Anti-TNF Crohn’s disease Upper gastrointestinal tract Eligibility Alkylating agents Vedolizumab CARCINOGENESIS Colonic epithelial primary cells Eradication Colorectal cancer Dysbiosis PCR Microbiote Patients experience Contraindication Disability Primary sclerosing cholangitis Immune cells Consensus IL23 Cancer MICROBIOTA Fecal microbiota HIV MORTALITY Colon Gene expression Ustekinumab Neoadjuvant chemotherapy Gènes Clinical trial Helicobacter pylori Thérapie ciblée MALT Safety Clinical guidelines Therapeutics IL12 Drug Rituximab plus chlorambucil Inclusion Disease Progression Ulcerative colitis Stricture Small molecules Crohn's disease Gene methylation Patient-reported outcome Venous thromboembolism MARKER Tuberculosis Bacteria DNA methylation T1118 translocation COLON-CANCER Intestinal crypts Inhibitor Colorectal cancer Colibactin and lipids Heart disease risk factors Epigenetics Colon cancer Biologics Rituximab Tailored therapy Over 80s Résistance DNA METHYLATION Colectomy Screening Immunosuppressant Anti-TNF agents Cell adhesion Epigénétiques Maintenance therapy Parvimonas micra Microbiota Disease progression Surgery RISK Acceptability Inflammatory bowel disease Bactéries Resistance Algorithm Méthylation Methylation Inflammatory Bowel Diseases Original Article Clinical 18 FDG-PET/CT Dysbiose Effectiveness Cost effectiveness Biomarker Inflammatory bowel diseases IBD Survival Monitoring Kidney diseases Genes Endoscopic treatment